Biotech research and drug discovery by Nurix Therapeutics
Nurix Therapeutics to present new Phase 1a1b study data on BTK degrader bexobrutideg in CLLSLL
Nurix Therapeutics announced it will share new and updated efficacy and safety results from its ongoing Phase 1a1b clinical study of the oral BTK degrader, bexobrutideg, in patients with relapsed ...
BTK degrader clinical program progresses as Nurix Therapeutics delivers Q3 2026 results
Nurix Therapeutics announced its financial results for the third quarter of 2026, reporting significant clinical progress in its investigational BTK degrader program. The company also stated it ...
Nurix Therapeutics enrolls first patient in Phase 1b2 trial of oral BTK degrader for CLL
Nurix Therapeutics has announced enrollment of the first patient in its Phase 1b2 study investigating its oral BTK degrader, bexobrutideg, in combination with venetoclax for the treatment of ...
Gilead Sciences extends Nurix Therapeutics partnership by two years in oncology research
Nurix Therapeutics has extended its oncology research collaboration with Gilead Sciences by an additional two years. The company will receive a $10 million fee for the extension. Nurix ...
Nurix Therapeutics reaches 7 million dollar milestone in Pfizer collaboration
Nurix Therapeutics has achieved a 7 million dollar milestone payment as part of its strategic collaboration with Pfizer. The partnership centers on the discovery and development of degrader ...
Investor interest expected as Nurix Therapeutics plans fireside chats at key healthcare events
Nurix Therapeutics will participate in a series of fireside chats at prominent healthcare investor conferences scheduled for September. The biotech company announced its plans via a recent ...
Nurix Therapeutics appoints Wes Burwell as chief human resources officer to advance internal culture
Nurix Therapeutics announced the appointment of Wes Burwell as its new chief human resources officer. Burwell brings extensive experience in the biotechnology sector, with a proven record of ...
Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study
Nurix Therapeutics has launched its DAYBREAK-CLL-201 clinical trial to evaluate bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The study ...
Nurix Therapeutics surges with new oral BTK degrader bexobrutideg momentum in CLL treatment
Nurix Therapeutics is seeing growing momentum for BTK degradation strategies in the treatment of relapsed and refractory chronic lymphocytic leukemia (CLL). In a recent interview with OncLive, ...
Nurix Therapeutics forges strategic partnership with Roche to accelerate bexobrutideg program
Nurix Therapeutics reported its financial results for the second quarter of 2026, emphasizing significant advancement in its development pipeline. The company announced a new global ...
Nurix Therapeutics enters partnership with Roche to advance targeted protein degradation therapies
Nurix Therapeutics has announced a strategic partnership with Roche to develop first-in-class targeted protein degradation therapies aimed at patients with significant unmet medical needs. This ...
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU
Nurix Therapeutics announced the presentation of new preclinical and Phase 1 translational data focused on its investigational therapy, bexobrutideg (NX-5948), for chronic spontaneous urticaria ...
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026
Nurix Therapeutics announced that updated efficacy and safety data from its ongoing Phase 1a b clinical trial of the BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic ...
